Asian Science Citation Index is committed to provide an authoritative, trusted and significant information by the coverage of the most important and influential journals to meet the needs of the global scientific community.  
ASCI Database
308-Lasani Town,
Sargodha Road,
Faisalabad, Pakistan
Fax: +92-41-8815544
Contact Via Web
Suggest a Journal
American Journal of Drug Discovery and Development
Year: 2017  |  Volume: 7  |  Issue: 1  |  Page No.: 33 - 38

Comparative Emetogenicity Study of Cisplatin Alone and in Combination Regimen on Cancer Patients of Bangladesh

A. Sarwar, M.S. Rahman, T.B. Huq, K. Biswas, M.I. Hussain, J.F. Chaity, T. Begum, Md. E. Haque, A. Islam and Mst. M. Begum    

Abstract: Background and Objective: To compare the prevalence of acute vomiting between patients receiving cisplatin as monotherapy or cisplatin in a combination regimen. Materials and Methods: The study was conducted at Delta Hospital Dhaka on a total of 70 patients (44 male and 26 female). The patients received either cisplatin alone or cisplatin with the following chemotherapeutic agents-docetaxel and 5 fluorouracil, docetaxel, etoposide, doxorubicin and capecitabine. The study was conducted in patients receiving chemotherapy for a total of the first 3 cycles. The patients were told to record the number of episodes of vomiting they experienced during the first 24 h after chemotherapy at each cycle. All 70 patients received prechemotherapy antiemetics a combination of 5HT3 receptor antagonist (ondansetron or palanosetron) and dexamethasone prior to chemotherapy. Results: In patients receiving the combination chemotherapy of cisplatin+docetaxel+5 FU experienced the lowest incidence of acute vomiting and cisplatin+capecitabine receiving patients experienced highest incidence of acute vomiting. All the other combination therapy resulted in emesis comparatively similar to that of cisplatin. In all the regimens except for cisplatin+etoposide the percentage of patients experiencing acute vomiting reduced along with progressive cycles. Conclusion: When cisplatin is given in combination regimen except for the combination regimen of cisplatin+capecitabine there is no significant increase in emesis between patients receiving cisplatin alone or in combination therapy.

Cited References   |    Fulltext    |   Related Articles   |   Back
   
 
 
 
  Related Articles

 
 
 
 
 
 
 
 
 
Copyright   |   Desclaimer   |    Privacy Policy   |   Browsers   |   Accessibility